MA51004A - Nouveaux analogues spirobicycliques - Google Patents
Nouveaux analogues spirobicycliquesInfo
- Publication number
- MA51004A MA51004A MA051004A MA51004A MA51004A MA 51004 A MA51004 A MA 51004A MA 051004 A MA051004 A MA 051004A MA 51004 A MA51004 A MA 51004A MA 51004 A MA51004 A MA 51004A
- Authority
- MA
- Morocco
- Prior art keywords
- spirobicyclic
- analogues
- new
- spirobicyclic analogues
- new spirobicyclic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/94—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom spiro-condensed with carbocyclic rings or ring systems, e.g. griseofulvins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/40—Heterocyclic compounds containing purine ring systems with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/14—Pyrrolo-pyrimidine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/167—Purine radicals with ribosyl as the saccharide radical
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762596441P | 2017-12-08 | 2017-12-08 | |
| EP18163867 | 2018-03-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA51004A true MA51004A (fr) | 2020-10-14 |
Family
ID=64664279
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA051004A MA51004A (fr) | 2017-12-08 | 2018-12-06 | Nouveaux analogues spirobicycliques |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US11059850B2 (fr) |
| EP (2) | EP4385996A3 (fr) |
| JP (1) | JP7352544B2 (fr) |
| KR (1) | KR20200097280A (fr) |
| CN (1) | CN111479817B (fr) |
| AU (1) | AU2018379456B2 (fr) |
| BR (1) | BR112020010815A2 (fr) |
| CA (1) | CA3084449A1 (fr) |
| ES (1) | ES2978117T3 (fr) |
| IL (1) | IL275129B2 (fr) |
| MA (1) | MA51004A (fr) |
| MX (1) | MX2020005944A (fr) |
| WO (1) | WO2019110734A1 (fr) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI870767B (zh) | 2015-08-26 | 2025-01-21 | 比利時商健生藥品公司 | 使用作為prmt5抑制劑之新穎經6-6雙環芳香環取代之核苷類似物 |
| MX2019003843A (es) | 2016-10-03 | 2019-06-24 | Janssen Pharmaceutica Nv | Análogos novedosos de carbanucleósidos sustituidos de sistema anular monocíclico y bicíclico para su uso como inhibidores de prmt5. |
| CA3049739A1 (fr) | 2017-02-27 | 2018-08-30 | Janssen Pharmaceutica Nv | Utilisation de biomarqueurs dans l'identification de patients atteints d'un cancer sensibles a un traitement avec un inhibiteur de prmt5 |
| BR112020010815A2 (pt) * | 2017-12-08 | 2020-11-10 | Janssen Pharmaceutica Nv | análogos espirobicíclicos |
| US11077101B1 (en) | 2018-07-18 | 2021-08-03 | Tango Therapeutics, Inc. | Compounds and methods of use |
| JP7609798B2 (ja) * | 2019-03-25 | 2025-01-07 | カリフォルニア インスティチュート オブ テクノロジー | Ｐｒｍｔ５インヒビター及びその使用 |
| TW202112375A (zh) | 2019-06-06 | 2021-04-01 | 比利時商健生藥品公司 | 使用ｐｒｍｔ５抑制劑治療癌症之方法 |
| BR112021024457A2 (pt) * | 2019-06-12 | 2022-01-18 | Janssen Pharmaceutica Nv | Intermediários espirobicíclicos |
| WO2021086879A1 (fr) | 2019-10-28 | 2021-05-06 | Tango Therapeutics, Inc. | Composés et procédés d'utilisation |
| BR112022010495A2 (pt) * | 2020-01-07 | 2022-09-06 | Pfizer | Método de tratamento da psoríase e outras condições auto-imunes com um inibidor prmt5 |
| CA3176912A1 (fr) | 2020-07-31 | 2022-02-03 | Tango Therapeutics, Inc. | Derives de piperidine-1-yl-n-pyridine-3-yl-2-oxoacetamide utiles pour le traitement des cancers deficients en mtap et/ou a accumulation de mta |
| US12492178B2 (en) | 2021-09-01 | 2025-12-09 | Empathbio, Inc. | Stable polymorph of R-MDMA HCl |
| WO2023129958A2 (fr) | 2021-12-28 | 2023-07-06 | ATAI Life Sciences AG | Promédicaments libérant de l'oxyde nitrique de mda et mdma |
| WO2026008533A1 (fr) | 2024-07-01 | 2026-01-08 | Janssen Pharmaceutica Nv | Inhibiteurs de prmt5 pour le traitement d'adénomes |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR901228A (fr) | 1943-01-16 | 1945-07-20 | Deutsche Edelstahlwerke Ag | Système d'aimant à entrefer annulaire |
| US4224438A (en) | 1970-07-14 | 1980-09-23 | Boehringer Mannheim Gmbh | Adenosine-5'-carboxylic acid amides |
| US6143749A (en) * | 1995-06-07 | 2000-11-07 | Abbott Laboratories | Heterocyclic substituted cyclopentane compounds |
| EP0970342A1 (fr) * | 1997-03-13 | 2000-01-12 | Peter Spielberger | Etui pour armes legeres |
| CN1331326A (zh) | 2000-06-30 | 2002-01-16 | 上海博德基因开发有限公司 | 一种新的多肽——人精氨酸甲基转移酶(hrmt)32.12和编码这种多肽的多核苷酸 |
| AU2002351077A1 (en) | 2001-11-05 | 2003-05-19 | Exiqon A/S | Oligonucleotides modified with novel alpha-l-rna analogues |
| US7034147B2 (en) | 2001-11-29 | 2006-04-25 | Irm Llc | Nucleoside analog libraries |
| PL372145A1 (en) | 2002-02-19 | 2005-07-11 | Cv Therapeutics, Inc. | Partial and full agonists of a sb 1 /sb adenosine receptors |
| US20040043959A1 (en) | 2002-03-04 | 2004-03-04 | Bloom Laura A. | Combination therapies for treating methylthioadenosine phosphorylase deficient cells |
| AU2002951247A0 (en) | 2002-09-06 | 2002-09-19 | Alchemia Limited | Compounds that interact with kinases |
| WO2005005450A1 (fr) | 2003-07-15 | 2005-01-20 | Mitsui Chemicals, Inc. | Procede de synthese d'un bisdinucleoside cyclique |
| WO2005065150A2 (fr) | 2003-12-19 | 2005-07-21 | Koronis Pharmaceuticals, Inc. | Heterocycles mutagenes |
| EP1844062A2 (fr) | 2005-01-21 | 2007-10-17 | Methylgene, Inc. | Inhibiteurs d'adn-methyltransferase |
| EP2043635A2 (fr) | 2006-06-29 | 2009-04-08 | Astex Therapeutics Limited | Combinaisons pharmaceutiques |
| US20080132525A1 (en) | 2006-12-04 | 2008-06-05 | Methylgene Inc. | Inhibitors of DNA Methyltransferase |
| EP3587434A1 (fr) | 2008-09-23 | 2020-01-01 | Alnylam Pharmaceuticals Inc. | Modifications chimiques de monomères et d'oligonucléotides avec des composants click capables de conjugaison de ligands |
| US8323918B2 (en) | 2008-12-12 | 2012-12-04 | University Of South Carolina | Chloroacetamidine based inhibitors and activity based probes for the protein arginine methytransferases |
| MX2012007026A (es) | 2009-12-18 | 2013-03-18 | Joslin Diabetes Center Inc | Compuestos que promueven la replicacion de celula beta y metodos de su uso. |
| WO2012012465A1 (fr) | 2010-07-19 | 2012-01-26 | Clarke, Michael, O'neil Hanrahan | Procédés de préparation de promédicaments au phosphoramidate pur au plan diastéréomère |
| WO2012082436A2 (fr) | 2010-12-03 | 2012-06-21 | Epizyme, Inc. | Modulateurs d'histone méthyltransférase et leurs procédés d'utilisation |
| EP2646454B1 (fr) | 2010-12-03 | 2015-07-08 | Epizyme, Inc. | Modulateurs à base de 7-déazapurine de l'histone méthyltransférase et procédés d'utilisation de ceux-ci |
| EP2651885A1 (fr) | 2010-12-16 | 2013-10-23 | Abbvie Inc. | Composés antiviraux |
| ES2587512T3 (es) | 2011-04-04 | 2016-10-25 | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services | Derivados de 2'-O-aminooximetil nucleósido para su uso en la síntesis y modificación de nucleósidos, nucleótidos y oligonucleótidos |
| EP2771012A4 (fr) | 2011-10-24 | 2015-06-24 | Glaxosmithkline Ip No 2 Ltd | Nouveaux composés |
| US20150057243A1 (en) | 2012-04-02 | 2015-02-26 | Northern University | Compositions and Methods for the Inhibition of Methyltransferases |
| WO2014035140A2 (fr) | 2012-08-30 | 2014-03-06 | Kainos Medicine, Inc. | Composés et compositions pour la modulation de l'activité histone méthyltransférase |
| US20140100184A1 (en) | 2012-08-31 | 2014-04-10 | Baylor College Of Medicine | Selective inhibitors of histone methyltransferase dot1l |
| PL2935222T3 (pl) | 2012-12-21 | 2019-02-28 | Epizyme Inc | Inhibitory PRMT5 i ich zastosowania |
| WO2014100695A1 (fr) | 2012-12-21 | 2014-06-26 | Epizyme, Inc. | Inhibiteurs de prmt5 et leurs utilisations |
| US8940726B2 (en) | 2012-12-21 | 2015-01-27 | Epizyme, Inc. | PRMT5 inhibitors and uses thereof |
| EP2935241A1 (fr) | 2012-12-21 | 2015-10-28 | Epizyme, Inc. | Inhibiteurs de prmt5 et leurs utilisations |
| EP2975938A4 (fr) | 2013-03-15 | 2017-02-15 | Ohio State Innovation Foundation | Inhibiteurs de prmt5 et leurs procédés d'utilisation |
| WO2015106025A1 (fr) | 2014-01-09 | 2015-07-16 | The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone | Benzoxazine substituée et composés associés |
| EP3160477A4 (fr) | 2014-06-25 | 2018-07-04 | Epizyme, Inc. | Inhibiteurs de prmt5 et leurs utilisations |
| EP3901159A1 (fr) | 2014-07-01 | 2021-10-27 | Millennium Pharmaceuticals, Inc. | Composés hétéroaryles utiles en tant qu'inhibiteurs de l'enzyme d'activation de la protéine sumo |
| CU20170105A7 (es) | 2015-02-24 | 2017-10-05 | Pfizer | Derivados de nucleosidos sustituidos útiles como agentes antineoplásicos |
| TWI870767B (zh) * | 2015-08-26 | 2025-01-21 | 比利時商健生藥品公司 | 使用作為prmt5抑制劑之新穎經6-6雙環芳香環取代之核苷類似物 |
| CA3016096C (fr) * | 2016-03-10 | 2023-10-17 | Janssen Pharmaceutica Nv | Analogues de nucleosides substitues destines a etre utilises en tant qu'inhibiteurs de prmt5 |
| WO2018065365A1 (fr) | 2016-10-03 | 2018-04-12 | Janssen Pharmaceutica Nv | Nouveaux analogues de carbanucléoside substitués par un système cyclique, monocyclique et bicyclique destinés à être utilisés en tant qu'inhibiteurs de prmt5 |
| MX2019003843A (es) | 2016-10-03 | 2019-06-24 | Janssen Pharmaceutica Nv | Análogos novedosos de carbanucleósidos sustituidos de sistema anular monocíclico y bicíclico para su uso como inhibidores de prmt5. |
| CA3049739A1 (fr) | 2017-02-27 | 2018-08-30 | Janssen Pharmaceutica Nv | Utilisation de biomarqueurs dans l'identification de patients atteints d'un cancer sensibles a un traitement avec un inhibiteur de prmt5 |
| BR112020010815A2 (pt) * | 2017-12-08 | 2020-11-10 | Janssen Pharmaceutica Nv | análogos espirobicíclicos |
-
2018
- 2018-12-06 BR BR112020010815-4A patent/BR112020010815A2/pt unknown
- 2018-12-06 WO PCT/EP2018/083808 patent/WO2019110734A1/fr not_active Ceased
- 2018-12-06 CA CA3084449A patent/CA3084449A1/fr active Pending
- 2018-12-06 CN CN201880078974.8A patent/CN111479817B/zh active Active
- 2018-12-06 JP JP2020530597A patent/JP7352544B2/ja active Active
- 2018-12-06 US US16/769,793 patent/US11059850B2/en active Active
- 2018-12-06 KR KR1020207017711A patent/KR20200097280A/ko active Pending
- 2018-12-06 EP EP24162318.0A patent/EP4385996A3/fr not_active Withdrawn
- 2018-12-06 IL IL275129A patent/IL275129B2/en unknown
- 2018-12-06 MX MX2020005944A patent/MX2020005944A/es unknown
- 2018-12-06 EP EP18816013.9A patent/EP3720865B1/fr active Active
- 2018-12-06 AU AU2018379456A patent/AU2018379456B2/en active Active
- 2018-12-06 ES ES18816013T patent/ES2978117T3/es active Active
- 2018-12-06 MA MA051004A patent/MA51004A/fr unknown
-
2021
- 2021-06-10 US US17/344,261 patent/US11702441B2/en active Active
-
2023
- 2023-05-18 US US18/320,071 patent/US12145961B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3720865C0 (fr) | 2024-03-13 |
| US11059850B2 (en) | 2021-07-13 |
| ES2978117T3 (es) | 2024-09-05 |
| RU2020122212A (ru) | 2022-01-10 |
| US20210380627A1 (en) | 2021-12-09 |
| JP7352544B2 (ja) | 2023-09-28 |
| BR112020010815A2 (pt) | 2020-11-10 |
| AU2018379456B2 (en) | 2022-11-24 |
| IL275129A (en) | 2020-07-30 |
| MX2020005944A (es) | 2020-08-24 |
| EP4385996A2 (fr) | 2024-06-19 |
| EP4385996A3 (fr) | 2024-07-31 |
| EP3720865A1 (fr) | 2020-10-14 |
| US20200369707A1 (en) | 2020-11-26 |
| RU2020122212A3 (fr) | 2022-01-10 |
| IL275129B1 (en) | 2023-06-01 |
| CA3084449A1 (fr) | 2019-06-13 |
| IL275129B2 (en) | 2023-10-01 |
| US11702441B2 (en) | 2023-07-18 |
| JP2021505582A (ja) | 2021-02-18 |
| EP3720865B1 (fr) | 2024-03-13 |
| US20230303612A1 (en) | 2023-09-28 |
| WO2019110734A1 (fr) | 2019-06-13 |
| CN111479817B (zh) | 2023-03-21 |
| CN111479817A (zh) | 2020-07-31 |
| AU2018379456A1 (en) | 2020-06-25 |
| US12145961B2 (en) | 2024-11-19 |
| KR20200097280A (ko) | 2020-08-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA51004A (fr) | Nouveaux analogues spirobicycliques | |
| DK3731771T3 (da) | V462033dk00 | |
| CL2018000524S1 (es) | Golilla | |
| EP3589248A4 (fr) | Cryothérapies | |
| DE202018003363U8 (de) | Handgelenkssphygmomanometer | |
| MA45430A (fr) | Analogues de célastrol | |
| EP3588580A4 (fr) | Diode schottky mos à tranchée | |
| DK3351526T3 (da) | Diisopentylterephthalat | |
| DK3568655T3 (da) | Rekuperator | |
| EP3546031A4 (fr) | Trampoline | |
| DK3571580T3 (da) | Load-logical-and-shift-guarded-instruktion | |
| DK3612237T3 (da) | Genterapi | |
| EP3611402A4 (fr) | Servocylindre | |
| PL3648604T3 (pl) | Mieszaniny grzybobójcze mefentriflukonazolu | |
| EP3684343A4 (fr) | Superparticules améliorées | |
| DK3445742T3 (da) | Krystallin tapentadolphosphat | |
| DK3576686T3 (da) | Brokbind | |
| DK3568506T3 (da) | Offeranode | |
| EP3585140A4 (fr) | Système de gestion de ruban d'épissurage | |
| DK3510051T3 (da) | Carboxylalkylchitosan | |
| DK3676276T3 (da) | Spirothietannukleosider | |
| DK3395159T3 (da) | Ballepresse | |
| DK3576718T3 (da) | Pastil | |
| DK3642136T3 (da) | Veksellad | |
| EP3612541A4 (fr) | Plasményléthanolamines cycliques |